Sequential Appearance and Ultrastructure of Amphophilic Cell Foci,Adenomas,and Carcinomas in the Liver of Male and Female Rats Treated with Dehydroepiandrosterone
Free accessResearch articleFirst published online September, 1995
Sequential Appearance and Ultrastructure of Amphophilic Cell Foci,Adenomas,and Carcinomas in the Liver of Male and Female Rats Treated with Dehydroepiandrosterone
Dehydroepiandrosterone (DHEA), a hormone of the adrenal cortex, acts as a peroxisome proliferator and hepatocarcinogen in rats upon long-term treatment with high doses in the diet. The aim of the present study was to identify the site of origin of hepatocellular neoplasms and the sequence of preneoplastic lesions. Twenty-five female and 25 male rats were given 0.6% DHEA in the diet; 25 animals of each sex were controls. Groups of 5 treated and untreated animals were sacrificed after 4, 20, 32, 70, and 84 wk. Amphophilic cell foci were detected after 32 wk of treatment; they developed from the liver parenchyma almost exclusively in the vicinity of portal tracts. Adenomas of the amphophilic or amphophilic/tigroid cell phenotype were observed at 70 wk of treatment. Highly differentiated hepatocellular carcinomas presenting a similar cellular phenotype occurred after 70-84 wk. The incidence of hepatocellular carcinomas was 44% in female and 11% in male rats. Ultrastructural studies of the amphophilic cell foci and tumors revealed a marked proliferation of mitochondria and a moderate proliferation of peroxisomes in all lesions. In addition, a very strong peroxisome proliferation was observed in perivenular hepatocytes in the liver of female rats. Peroxisomes usually lacked core and showed flocculent matrices. In male rats, weak peroxisomal proliferation was observed. Typical morphological abnormalities of these peroxisomes were paracrystalline inclusions of striated appearance. Although the most prominent peroxisome proliferation was observed in perivenular hepatocytes, these cells did not seem to be involved in tumor development. In contrast, the morphological similarity of the amphophilic cell foci and the amphophilic/tigroid cell adenomas and carcinomas, their coincident localization near portal tracts, and the sequential appearance of these lesions suggest that the amphophilic cell foci represent an early stage in DHEA-induced hepatocellular neoplasia. Mitochondrial proliferation as the most prominent feature in all stages of this model of hepatocarcinogenesis may offer a new approach for analysis of hepatocarcinogenesis induced by DHEA and possibly other peroxisomal proliferators.
Angermüller S. and Fahimi HD (1981). Selective cytochemical localization of peroxidase, cytochrome oxidase and catalase in rat liver with 3,3'-diaminobenzidine. Histochemistry71: 33-44.
2.
Bannasch, P. (1968). The cytoplasm of hepatocytes during carcinogenesis. Electron and light microscopical investigations of the nitrosomorpholine-intoxicated rat liver. Rec. Res. Cancer Res. 19: 1-100.
3.
Bannasch P. (1976). Cytology and cytogenesis of neoplastic (hyperplastic) hepatic nodules. Cancer Res. 36: 2555-2562.
4.
Bannasch P., Hacker HJ, Klimek F., and Mayer D. (1984). Hepatocellular glycogenosis and related pattern of enzymatic changes during hepatocarcinogenesis. Adv. Enzyme Reg. 22: 97-121.
5.
Bannasch P., Krech R., and Zerban H. (1978). Morphogenese und Mikromorphologie epithelialer Nierentumoren bei Nitrosomorpholin-vergifteten Rat-ten. III. Onkocytentubuli und Onkocytome. Z. Krebsforsch. 92: 87-104.
6.
Bannasch P. and Zerban H. (1992). Predictive value of hepatic preneoplastic lesions as indicators of carcinogenic response. In: Mechanism of Carcinogenesis in Risk Identification, H Vainio, PN Magee, DB McGregor , and AJ McMichael (eds). IACR, Lyon, pp.389-427.
7.
Bannasch P., Zerban H., and Hacker HJ (1978). Foci of altered hepatocytes, rat. In: Digestive System, TC Jones, U Mohr, and RD Hunt (eds). Springer, Berlin, Heidelberg, pp. 10-38.
8.
Baulieu EE (1962). Studies of conjugated 17-ketosteroids in a case of adrenal tumor. J. Clin. Endocrinol. Metab. 22: 501-510.
9.
Baumgart E., Stegmeier KH, Schmidt FH, and Fahimi HD (1987). Proliferation of peroxisomes in pericentral hepatocytes of rat liver after administration of a new hypocholesterolemic agent (BM 15766) . Lab. Invest. 56: 554-564.
10.
Beier K. (1992). Untersuchung zur Plastizitdt von Peroxisomen. Habilitationsschrift, Fakultat für Naturwissenschaftliche Medizin, Ruprecht-Karls-Universitat, Heidelberg .
11.
Benner U., Hacker HJ, and Bannasch P. (1979). Electron microscopical demonstration of glucose-6-phosphatase in native cryostat sections fixed with glutaraldehyde through semipermeable membranes. Histochemistry65: 41-47.
12.
Boone CW, Kellogg AJ, and Malone WE (1990). Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res. 50: 2-9.
13.
Butterworth BE, Loury DJ, Smith-Oliver T., and Cattley RC (1987). The potential role of chemically induced hyperplasia in the carcinogenic activity of the hypolipidemic carcinogens. Toxicol. Indust. Health3: 129-147.
14.
Cleary MP (1990). Effect of dehydroepiandrosterone treatment on liver metabolism in rats. Int. J. Biochem. 22: 205-210.
15.
Cleary MP, Hood SS, Chando C., Hansen CT, and Billheimer JT (1984). Response of sucrose-fed BHE rats to dehydroepiandrosterone . Nutr. Res. 4: 485-494.
16.
Cleary MP, Shepherd A., Zisk J., and Schwartz A. (1983). Effect of dehydroepiandrosterone on body weight and food intake in rats. Nutr. Behav. 1 : 127-136.
17.
Cleveland WS and Grosse E. (1991). Computational method for local regression. Stat. Comput. 1 : 47-62.
18.
Fahimi DF, Reinicke A., Sujatta M., Yokota S., and Ozel M. (1982) The short- and long-term effects of bezafibrate in the rat. Ann. N. Y. Acad. Sci. 386: 111-135.
19.
Farber E. (1992). Hepatocarcinogenesis: How do peroxisome proliferators relate?J. Am. College Toxicol. 11:363-367.
20.
Frenkel RA, Slaughter CA, Orth K., Moosmaw CR, Hicks SH, Snyder JM, Bennett M., Prough RA, Put-man RS, and Milewich L. (1990). Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding. J. Steroid Biochem. 35: 333-342.
21.
Garcea R., Daino L., Pascale R., Frasetto S., Cozzolino P., Ruggiu ME, and Feo F. (1987). Inhibition by dehydroepiandrosterone of liver preneoplastic foci formation in rats after initiation-selection in experimental carcinogenesis. Toxicol. Pathol. 15: 164-169.
22.
Gordon GB, Shantz LM, and Talalay P. (1987). Modulation of growth differentiation and carcinogenesis by dehydroepiandrosterone. Adv. Enzyme Regul. 26: 355-382.
23.
Gorgas K. and Krisans SK( 1989). Zonal heterogeneity of peroxisome proliferation and morphology in rat liver after gemfibrozil treatment. J. Lipid Res. 30: 1859-1875.
24.
Gusek W. (1975). Die Ultrastruktur Cycasin-induzierter Nierenadenome . Virchows Arch. [A] 365: 221-237.
25.
Hamperl H. (1962). Benign and malignant oncocytoma. Cancer15: 1019-1027
26.
Harada T., Maronpot RR, Morris RW, and Boorman GA (1989). Observation on altered hepatocellular foci in National Toxicology Program two-year carcinogenicity studies in rats. Toxicol. Pathol. 17: 690-706.
27.
Hayashi F., Tamura H., Yamada J., Kasai H., and Suga T. (1994). Characteristics of the hepatocarcinogenesis caused by dehydroepiandrosterone, a peroxisome proliferator, in male F-344 rats. Carcinogenesis15: 2215-2219.
28.
Hertz R., Aurbach R., Hashimoto T., and Bar-Tana J. (1991). Thyromimetic effect of peroxisomal proliferators in rat liver. Biochem. J. 274: 745-751.
29.
Hobe G., Hillesheim HG, Schön R., Reddersen G., Knappe R., Bannasch P., and Mayer D. (1994). Sex differences in dehydroepiandrosterone metabolism in the rat: Different plasma levels following ingestion of DHEA-supplemented diet and different metabolite patterns in plasma, bile and urine. Horm. Metab. Res. 26: 326-329.
30.
Hobe G., Hillesheim HG, Schön R., Ritter P., Reddersen G., Mayer D., and Bannasch P. (1994). Sex dif ferences in dehydroepiandrosterone (DHEA) metabolism in the rat. In: Proceedings of the 5th Symposium on the Analysis of Steroids, S Görög (ed). Akademiai Kiado, Budapest, pp. 383-390.
31.
Hruban Z. (1979). Ultrastructure of hepatocellular tumors. In: Liver Carcinogenesis, K Lapis and JV Johannessen (eds). Hemisphere, Washington, D.C., New York, London, pp. 233-261.
32.
Issemann I. and Green S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators . Nature (London) 347: 645-650.
33.
Kraupp-Grasl B., Huber W., Putz B., Gerbracht U., and Schulte-Hermann R. (1990 ). Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver. Cancer Res. 50:3701-3708.
34.
Kraupp-Grasl B., Huber W., Taper H., and Schulte-Hermann R. (1991 ). Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously. Cancer Res. 51:666-671.
35.
Liang KY and Zeger SL (1986). Longitudinal data analysis using generalized linear models. Biometrika73:13-22.
36.
Marsman SD and Popp JA (1994). Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643 . Carcinogenesis15: 111-117.
37.
Mohan PF and Cleary MP (1991) Effect of short-term effects of dehydroepiandrosterone treatment in rats on mitochondrial respiration. J. Nutr. 121: 240-250.
38.
Moore MA, Thamavit W., Tsuda H., Sato K., Ichihara A., and Ito N. (1986). Modifying influence of dehydroepiandrosterone and the development of dihydroxy-di-n-propylnitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis7:311-316.
39.
Nyce JW, Magee PN, Hard GC, and Schwartz AG (1984). Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in BALB/c mice by dehydroepiandrosterone. Carcinogenesis5: 57-62.
40.
Pashko LL, Hard GC, Rovito RJ, Williams JR, Sobel EL, and Schwartz AG (1985). Inhibition of 7,12-dimethylbenz[a]anthracene-induced skin papillomas and carcinomas by dehydroepiandrosterone and 3-β-methyl-androst-5-en-17-one in mice. Cancer Res.45: 164-166.
41.
Rao MS, Ide H., Alvares K., Subbarao V., Reddy JK, Hechter O., and Yeldandi AV (1993). Comparative effects of dehydroepiandrosterone and related steroids on peroxisome proliferation in rat liver. Life Sci. 52:1709-1716.
42.
Rao MS, Lalwani ND, Scarpelli DG, and Reddy JK (1982). The absence of γ-glutamyltranspeptidase activity in putative preneoplastic lesions and in hepatocellular carcinomas induced in rats by the hypolipidemic peroxisome proliferator WY-14,1643. Carcinogenesis3 : 1231-1233.
43.
Rao MS, Musunuri S., and Reddy JK (1992). Dehydroepiandrosterone-induced peroxisome proliferation in the rat liver. Pathobiology60: 82-86.
44.
Rao MS and Reddy JK (1987). Phenotypic properties of preneoplastic and neoplastic hepatic lesions induced by peroxisome proliferators. In: Peroxisomes in Biology and Medicine, HD Fahimi and H Sies (eds). Springer , Berlin, Heidelberg, pp. 263-272.
45.
Rao MS, Reid B., Ide H., Subbarao V., and Reddy JK (1994). Dehydroepiandrosterone-induced peroxisome proliferation in the rat: Evaluation of sex dif ferences. Proc. Soc. Exp. Biol. Med. 207: 186-190.
46.
Rao MS, Subbarao V., Kumar S., Yeldandi V., and Reddy JK (1992). Phenotypic properties of liver tumors induced by dehydroepiandrosterone in F-344 rats. Jpn. J. Cancer Res . 83: 1179-1183.
47.
Rao MS, Subbarao V., Yeldandi AV, and Reddy JK (1992). Hepatocarcinogenicity of dehydroepiandrosterone in the rat. Cancer Res. 52: 2977-2979.
48.
Reddy JK and Lalwani ND (1983). Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit. Rev. Toxicol. 12: 1-58.
49.
Reddy JK, Lalwani ND, Reddy MK, and Qureshi SA (1982). Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res. 42: 259-266.
50.
Reddy JK and Rao MS (1989). Oxidative DNA-damage caused by persistent peroxisome proliferation: Its role in hepatocarcinogenesis. Mutat. Res . 214: 63-68.
51.
Reznik-Schüller HM and Gregg M. (1983). Sequential morphologic changes during methapyrilene-induced hepatocellular carcinogenesis in rats . J. Natl. Cancer Inst. 71: 1021-1031.
52.
Roomi MW, Rao MS, Reddy JK, Cameron RG, and Farber E. (1987). Modulation of the phenotypic expression of rat hepatocyte nodules by a hypolipidemic agent, ciprofibrate (CP). Proc. Am. Assoc. Cancer Res. 28:568.
53.
Schulte-Hermann R., Timmermann-Trosiener I., and Schuppler J. (1983). Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Res . 43: 839-844.
54.
Schwartz AG (1979). Inhibition of spontaneous breast cancer formation in female C3H(AVY/a) mice by long term treatment with dehydroepiandrosterone. Cancer Res. 51:666-671.
55.
Schwartz AG and Tannen RH (1981). Inhibition of 7,12-dimethylbenz[a]anthracene-/and urethan-induced lung tumor formation in A/J mice by longterm treatment with dehydroepiandrosterone. Carcinogenesis2:1335-1337.
56.
Schwartz AG , Whitcomb JM, Nyce JW, Lewhart ML, and Pashko LL (1988). Dehydroepiandrosterone and structural analogs: A new class of cancer chemopreventive agents. Adv. Cancer Res. 51: 391-424.
57.
Shepherd A. and Cleary MP (1984). Metabolic alterations after dehydroepiandrosterone on body weight and food intake in rats. Nutr. Behav. 1 : 127-136.
58.
Sonka J. (1976) Dehydroepiandrosterone. In: Metabolic Effects. Monograph LXXI. Universita Karlova, Prague, pp. 1-171.
59.
Tagliaferro AR, Davis JR, Truchon S., and Van Hamont N. (1986). Effect of dehydroepiandrosterone acetate on metabolism, body weight and composition of male and female rats. J. Nutr. 116: 1977-1983.
60.
Tsuda H., Hacker HJ, Katayama H., Masui T., Ito N., and Bannasch P. (1986). Correlative histochemical studies on preneoplastic and neoplastic lesions in the kidney of rats treated with nitrosamines. Virchows Arch. [B] 51: 385-404.
61.
Weber E. and Bannasch P. (1994). Dose and time dependence of the cellular phenotype in rat hepatic preneoplasia and neoplasia induced by single oral exposure to N-nitrosomorpholine. Carcinogenesis15: 1219-1226.
62.
Weber E. and Bannasch P. (1994). Dose and time dependence of the cellular phenotype in rat hepatic preneoplasia and neoplasia induced in stop experiments by oral exposure to N-nitrosomorpholine. Carcinogenesis15: 1227-1234.
63.
Weber E. and Bannasch P. (1994). Dose and time dependence of the cellular phenotype in rat hepatic preneoplasia and neoplasia induced by continuous oral exposure to N-nitrosomorpholine. Carcinogenesis15: 1235-1242.
64.
Weber E., Moore MA, and Bannasch P. (1988). Enzyme histochemical and morphological phenotype of amphophilic foci and amphophilic/tigroid cell adenomas in rat liver after combined treatment with dehydroepiandrosterone and N-nitrosomorpholine. Carcinogenesis9: 1049-1054.
65.
Weber E., Moore MA, and Bannasch P. (1988). Phenotypic modulation of hepatocarcinogenesis and reduction in N-nitrosomorpholine-induced hemangiosarcoma and adrenal lesion development in Sprague-Dawley rats by dehydroepiandrosterone. Carcinogenesis9: 1191-1195.
66.
Wu HQ, Masset-Brown J., Tweedie DJ, Milewich L., Frenkel RA, Martin-Wixtrom C., Eastabrook RW, and Prough RA (1989). Induction of microsomal P-450 reductase and cytochrome P450IVA1 (P-450LAω) by dehydroepiandrosterone in rats: A possible peroxisomal proliferator. Cancer Res. 49: 2337-2343.
67.
Yamada J., Sakuma M.Ikeda T., Fukuda K., and Suga T. (1991). Characteristics of dehydroepiandrosterone as a peroxisome proliferator. Biochim. Biophys. Acta1092: 233-243.
68.
Yamada J., Sakuma M., Ikeda T., and Suga T. (1994). Activation of dehydroepiandrosterone as a peroxisome proliferator by sulfate conjugation. Arch. Biochem. Biophys . 313: 378-381.
69.
Yokoyama Y. , Tsuchida S., Hatayama I., Satoh K., Narita T., Rao MS, Reddy JK, Yamada J., Suga T., and Sato K. (1992). Loss of peroxisomal enzyme expression in preneoplastic and neoplastic lesions induced by peroxisome proliferators in rat livers. Carcinogenesis13: 256-269.
